Item 7.01 Regulation FD Disclosure.

On August 27, 2020, Akers Biosciences, Inc. (the "Company") issued a press release, attached hereto as Exhibit 99.1, announcing with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of the Company's SARS-CoV-2 vaccine candidate in mice. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.




Item 9.01       Financial Statements and Exhibits.



(d) Exhibits



Exhibit Number   Description
99.1               Press Release, dated August 27, 2020

© Edgar Online, source Glimpses